According to SNS Insider, the global Plasmid Purification Market was valued at USD 1.96 billion in 2024 and is expected to reach USD 4.74 billion by 2032, growing at a CAGR of 11.67% during the ...

Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.

Plasmids are essential for the development of viral vectors used to manufacture novel gene therapies and viral vaccines. Aldevron is supporting the innovation of drug developers in this space by ...

IMNN-001, based on IMUNON’s proprietary TheraPlas ® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed ...